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ABSTRACT
Therapeutic proteins are now established as a major class of medication with proven efficacy in treating
a wide range of diseases. The administration of such proteins to patients can lead to the development of
antibodies that are able to bind and eventually neutralise the protein administered. Many advances have
been made in understanding the immunogenicity of therapeutic proteins, but opinions are often
conflicting. Although it is important to understand more about the antibodies generated against
therapeutic proteins, the need for future research must not be neglected, so that other relevant factors
can be identified and addressed to maximise treatment benefits for patients.
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Several diseases, syndromes and disorders can be
treated effectively with therapeutic proteins
(including antibodies, whether human or not).
Some of these proteins, particularly when admin-
istered over a prolonged period of time, may elicit
an immune response, causing the generation of
antibodies that are able to bind to the protein
administered, and sometimes neutralise its bio-
logical and therapeutic activity [1]. Recently,
attention has focused mostly on the development
of neutralising antibodies (NAbs) and their
potential impact on treatment in a range of
therapeutic areas. Table 1 shows some examples
of therapeutic proteins to which an immune
response has been demonstrated.
In February 2006, a concept paper produced by
the European Medicines Agency emphasised the
importance of NAbs and recommended that
guidelines should be developed concerning
assessments of the immunogenicity of biotech-
nology-derived therapeutic proteins (http://
www.emea.Europe.eu/pdfs/human/biosililar/
24651105.en.pdf). The paper highlighted the fact
that treatment with such agents may induce an
unwanted immune response that, occasionally,
is clinically significant. In addition, it was
considered that guidance on the investigation
and assessment of immunogenicity may contrib-
ute to a more rational and systematic approach to
this issue by the pharmaceutical industry and
regulatory authorities. Topics to be addressed by
such guidelines should include the potential
consequences of immunogenicity (in terms of
the efficacy and safety of treatment), the predic-
tion of immunogenicity (with particular attention
to identifying product-, disease- and patient-
related risk-factors), and the development of
assays for monitoring humoral and cellular
immune responses to therapeutic proteins.
Numerous studies have addressed the phe-
nomenon of immunogenicity, and many advances
have been made in understanding the kinetics
of antibody development to some therapeutic
proteins; indeed, the classes of immunoglobulin
produced have been identified in many cases.
However, it is known that the proportion of
patients who experience seroconversion depends
on the commercial preparation of a specific drug.
There is also awareness that many factors have
the potential to influence the immunogenicity of
therapeutic proteins, including patient character-
istics, treatment-related factors (e.g., the dose,
route of administration, formulation and contam-
inants), and factors relating to the protein itself
(e.g., sequence variation, glycosylation and im-
proper folding) [1–3].
Nevertheless, many crucial questions regarding
immunogenicity remain unanswered.
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1. It is not known whether the production of
antibodies represents a breakdown of immune
tolerance to self-antigens, or if activation of the
classic humoral response is caused by the fact
that the protein is, in some ways, antigenically
distinct from the natural protein.
2. Little is known regarding the potential for cell-
mediated, rather than humoral, immune
responses against therapeutic proteins.
3. The antigenic epitopes of the different thera-
peutic proteins that are crucial for the devel-
opment of NAbs are also largely unknown.
4. Standardised and validated assays for NAbs
are often absent.
5. Conclusions regarding the clinical significance
of NAb development, at least in some in-
stances, remain controversial.
This last point is crucial and leads to a wider
issue regarding immunogenicity. Investigation of
the clinical impact of NAbs on therapeutic pro-
teins often yields conflicting results. Taking multi-
ple sclerosis (MS) as an example, an ability to
assess the impact of NAbs on the efficacy of
interferon (IFN)-b treatment often depends on the
specific design of the clinical study, the clinical
endpoint assessed, the duration of follow-up, and
the size of the study population [4–12]. The issue is
further confounded by the fact that measurements
of NAb development and titres can vary according
to the methods used for analysis, the timing of the
assessment (in terms of length of treatment and
disease course), and the disease status of the
patient. Additionally, and more importantly, dif-
ferent treatments can show superior efficacy to one
another, regardless of the NAb status of the patient
[13]. Therefore, although the explanation is clearly
far from complete, NAbs are regularly considered
to be the main reason behind a failure to respond
to IFN treatment in MS patients. However, immu-
nogenicity is only one potential cause of non-
response, and it is now known that many factors
other than NAbs (e.g., the pharmacogenomic
profile of a patient) may affect the response to
therapy [3,14–17]. Therefore, other reasons for
failure of therapy should also be investigated. It is
now >25 years since NAbs to IFN were first
reported [18], and while not wishing to belittle
the importance of NAbs, it seems that the undue
focus on NAbs has resulted in the loss of valuable
time during which non-response to treatment
might have been fully investigated.
In summary, inferences are being made
concerning the impact of NAbs on therapeutic
proteins, and their relationship to clinical out-
comes, without a full understanding of the science
behind the development of NAbs. Moreover, so
much attention is being given to NAbs, and their
potential link to a failure to respond to treatment,
that many patients who do not respond to
treatment, despite testing negative for NAbs,
and vice versa, are being forgotten; this is also
true for diseases other than MS. Certainly, ques-
tions remain to be answered regarding NAbs, but
investigations into immunogenicity should not be
performed at the expense of research into other
reasons for non-response to treatment. Careful
pharmacodynamic and proteomic studies may
enable the identification of markers that can allow
an assessment of the underlying immune status of
patient sub-populations in each specific disease.
Efforts should also be made, both by pharmaceu-
tical companies and by the scientific community,
to understand all the factors that may determine
why some patients do not demonstrate a response
to therapy. Otherwise, the full explanation for the
failure of treatment with therapeutic proteins may
remain unknown and unaddressed.
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